{
  "docId": "019de074-c46c-7261-862e-11078609bbd6",
  "docSlug": "94ed059236b735624310519badaf5152",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 32 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 32,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "customer_journey",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The funnel visualizes the drop-off from total diagnosed COPD patients to those currently on YUPELRI.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c46c-7261-862e-11078609bbd6/27",
  "deckHref": "/decks/019de074-c46c-7261-862e-11078609bbd6",
  "deckJsonHref": "/decks/019de074-c46c-7261-862e-11078609bbd6.json",
  "deckAnchorHref": "/decks/019de074-c46c-7261-862e-11078609bbd6#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Estimated 2021 YUPELRI Patient Funnel (US)",
      "attrs": null,
      "subkind": "funnel",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9f5274f-6fe4-48c1-a3f2-1342a3e28cf3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "1. American Lung Association. 2. Clarivate COPD Disease Landscape & Forecast US 2021. 3. Revefenacin COPD Joint Venture Research 2016. 4. Safka KA, et al. Chronic Obstr Pulm Dis 2017. 5. Mahler DA, et al. Chronic Obstr Pulm Dis 2019. 6. Armitage JM, Williams SJ Inhaler technique in the elderly. Age Ageing 1988 17:275-278. COPD, chronic obstructive pulmonary disease; DME, durable medical equipment; LAMA, long-acting muscarinic antagonist; PIFR, peak inspiratory flow rate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c1f5906-c830-41bb-a0a3-9a36ccc48cc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.41,
        "y": 0.42
      },
      "kind": "framework",
      "text": "Growth opportunities within numerous patient segments",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ec9fa57-c045-4038-83cb-48e538036c6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.52,
        "x": 0.44,
        "y": 0.21
      },
      "kind": "list",
      "text": "COPD is under-diagnosed; COPD patients with or without symptoms may be treated with rescue and/or maintenance therapies; Estimated patient counts from volume using average 'days of therapy' assumptions vary considerably across DME and retail channels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8c8664e-34b2-4a80-8634-e30b5c145d48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "Patent No 11,484,531, methods of treating COPD, expiring in 2039, is now listed in the Approved Drug Products with Therapeutic Equivalence Evaluations",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1f85e17-3ca8-4a10-841c-1b6a3827c356",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Substantial Opportunity for Further YUPELRI® Growth",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9503b67-279a-4b4c-854e-4f0bb689ee1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "Once-Daily Nebulized LAMA COPD treatment represents a sizeable niche market",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bfacf55-b647-45d5-90fe-3a97a700178d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "customer-journey-map",
      "slug": null,
      "matchId": "b8a35c8b-00c0-444f-823f-1802ba112b29",
      "evidence": "The slide uses a funnel to represent the patient journey from diagnosis to treatment, followed by specific segment opportunities.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}